Sibrotuzumab
Sibrotuzumab is a humanized monoclonal antibody intended for the treatment of cancer. It binds to FAP[1][2]
References
- ^ Scott, AM; Wiseman, G; Welt, S; Adjei, A; Lee, FT; Hopkins, W; Divgi, CR; Hanson, LH et al. (2003). "A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer". Clinical cancer research : an official journal of the American Association for Cancer Research 9 (5): 1639–47. PMID 12738716.
- ^ Kloft, C; Graefe, EU; Tanswell, P; Scott, AM; Hofheinz, R; Amelsberg, A; Karlsson, MO (2004). "Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients". Investigational new drugs 22 (1): 39–52. doi:10.1023/B:DRUG.0000006173.72210.1c. PMID 14707493.
|
|
|
| Tumor ("-t(u[m])-") |
|
Human ("-tumu-")
|
|
|
|
Mouse ("-tumo-")
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|